Multiple metabolic comorbidities and their consequences among patients with peripheral arterial disease

Young Shin Park¹, Gi Wook Ryu¹,²,³, Mona Choi¹*

¹ Mo-Im Kim Nursing Research Institute, Yonsei University College of Nursing, Seoul, Republic of Korea, ² College of Nursing and Brain Korea 21 FOUR Project, Yonsei University College of Nursing, Seoul, Republic of Korea, ³ Department of Nursing, Hanse University, Gyeonggi-do, Republic of Korea

* monacho@yuhs.ac

Abstract

Older adults with peripheral arterial disease (PAD) have increased risks of major cardiovascular events and hospitalization. Metabolic comorbidities, such as hypertension, diabetes mellitus, and dyslipidemia, are common risk factors for these unfavorable health events. This study aimed to determine how multiple metabolic comorbidities affect the risk of adverse health outcomes in older adults with PAD. A retrospective cohort study was adopted using administrative claim data from the Health Insurance Review and Assessment Service Agency. The study sample included 3,122 older adults (≥ 65 years old) with at least one PAD diagnosis in an inpatient setting from 2011 to 2013 and who had at least one follow-up visit after hospitalization by 2018. The three metabolic comorbidities were defined as having at least two diagnostic claims or one prescription per year of anti-hypertensive, anti-diabetic, or anti-dyslipidemic medications for the corresponding diagnosis. The outcome variables included major adverse cardiovascular events (MACEs) and major adverse limb events (MALE). Kaplan-Meier survival curves demonstrated that PAD patients with more metabolic comorbidities had shorter MACE-free and MALE-free periods. Adjusted Cox proportional hazards analyses suggested significant additive effects of multiple metabolic comorbidities on increased risks of MACE and MALE among older adults with PAD. Lower socioeconomic status and non-metabolic comorbidities also increased the risk of MACE. Male sex, being young-old (65–74 years), and a higher proportion of inpatient claims increased the risk of MALE. The findings of this study suggest the need for a comprehensive care program for older adults with PAD and metabolic comorbidities. In addition, the healthcare utilization pattern should be considered when designing preventive care for older patients with comorbidities to manage PAD at an earlier stage.

Introduction

Globally, more than 200 million people suffered from peripheral arterial disease (PAD) in 2010, with an increase in PAD incidence of 23.5% in the past ten years [1]. In a study using the
US healthcare administrative database from 2003 to 2008, PAD had a mean annual prevalence of 10.7% and a mean annual incidence of 2.4% [2]. The prevalence of PAD ranged from 3% to 4% in middle-aged adults and 13% to 14% in older adults [3]. The global disease burden from death and disability due to PAD has also increased over the 20 years from 1990 to 2010 [4]. PAD is also the third leading cause of atherosclerotic vascular disease [1]. The economic costs associated with hospitalization due to PAD are higher than those of coronary artery disease or cerebrovascular disease, which need vascular interventions as major cardiovascular events [5]. People with PAD suffer from functional limitations related to symptoms of claudication or limb loss, which result in a decrease in quality of life [6].

A previous study revealed higher rates of cardiovascular death events and the combined outcomes of major cardiovascular events (MACE), major adverse limb events (MALE), and hospitalization in PAD patients than in those people having coronary artery diseases [7]. Metabolic diseases are highly associated with PAD [8]. PAD patients have a higher risk of hypertension, diabetes mellitus, and lipid disorders than those without PAD [9, 10]. These comorbid metabolic diseases are also associated with increased risks of major cardiovascular events including myocardial infarction (MI), limb ischemia, or stroke as they share common causes or risk factors [11–13]. For example, diabetes concomitant with PAD is known to increase the risks of cardiovascular diseases. However, the magnitude of the risks attributed to diabetes differs based on other comorbidities present [14]. Previous studies have examined the negative impact of having a metabolic disease, either diabetes or vascular disease, in the setting of PAD. However, studies have not examined the pattern of coexisting metabolic diseases, such as hypertension, diabetes, and dyslipidemia, and their effects on PAD-related adverse health outcomes.

As these three metabolic diseases commonly coexist with PAD, it is important to focus on the influence of multiple metabolic comorbidities on the older and more vulnerable populations suffering from PAD. However, this pattern is less understood in older Korean populations. Thus, this study examined the association between multiple metabolic comorbidities, such as hypertension, diabetes, and dyslipidemia, and the risks of MACE and MALE among Korean older adults with PAD.

Materials and methods

Ethical approval and study design

This study was approved by the Yonsei University Institutional Review Board (Y-2019-0105). This study performed secondary data analysis through an observational and retrospective cohort study design, which analyzed patient-level individual data linking administrative claim data from the Health Insurance Review and Assessment Service Agency (HIRA) of South Korea.

Data source and study population

Korea adopts the single-payer system and the government-administered universal insurance healthcare system. The datasets used for this study were obtained from the HIRA administrative claim data. The study sample included PAD patients aged ≥ 65 years separated into three age groups (young-old: 65–74 years; old-old: 75–84 years; oldest-old: ≥85 years) with at least one claim of PAD diagnosis as a primary diagnosis in inpatient visits from January 2011 to December 2013 and had at least one follow-up outpatient or inpatient visit with any PAD diagnosis within one year after the index hospitalization [15]. An incident PAD patient was defined as an individual hospitalized with a primary diagnosis of PAD during the study period using the International Classification of Diseases, Tenth Revision (ICD-10) (I70.2, I73.8, I73.9, I74.3,
Patients with a PAD diagnosis 2 years before (2009–2010) the study period were excluded to include incident cases. The earliest date of PAD diagnosis, on or after January 2011, was defined as the baseline index date. We eliminated all cases with claims corresponding to either MACE or MALE before the study period. Finally, a total of 3,122 older adults with PAD were included for analysis (Fig 1).

**Independent variables**

Metabolic comorbidities were defined as having at least two claims per year of hypertension (HTN), type 1 or type 2 diabetes mellitus (DM), and dyslipidemia with ICD-10 diagnosis codes (HTN: I10, I11, I12, I13, I15; DM: E10, E11, E12, E13, E14; dyslipidemia: E78), or one claim with the prescription of anti-hypertensive, anti-diabetic, or anti-dyslipidemic medication per year under these diagnosis codes [15]. The details of ICD-10 codes for metabolic comorbidities are provided in the S1 Table.

This study aimed to quantitatively examine how metabolic comorbidities affect adverse health outcomes. We determined the number of participants in the cross tables with HTN or DM, HTN or dyslipidemia, and DM or dyslipidemia. Approximately 30% of the participants
(n = 952) had hypertension and dyslipidemia, making this the highest among the other overlapping patterns of paired metabolic diseases. Descriptive cross tables of the number and percentage of participants with HTN or DM, HTN or dyslipidemia, and DM or dyslipidemia are presented in S2 Table. Finally, the total number of metabolic comorbidities of hypertension, diabetes, or dyslipidemia was used as an independent variable to measure the adverse health outcomes.

Outcome variables
This study considered adverse health consequences that took place after the index date. These included major adverse cardiovascular events (MACEs), such as including myocardial infarction, ischemic stroke, and unstable or stable angina, and major adverse limb events (MALEs), such as major amputation (amputation of the extremities of the pelvis, thigh, upper arm/forearm/lower leg), minor amputation (hand/foot, finger/toe), revascularization, and open surgery [16–18]. The end of the follow-up period for this study was December 31, 2018 (censored). The details of ICD-10 codes for MACE are provided in the S3 Table and the HIRA procedures codes for MALE are provided in the S4 Table [18].

Covariate variables
Covariates including the age, sex, type of insurance (insured and others including medical aid and veterans), and the proportion of days covered (PDC), were calculated 3 months after the index date. An 80% PDC indicated good compliance [19–21]. The PDCs of anti-hypertensive, anti-diabetic, anti-dyslipidemic, and antiplatelet medications were included as binary variables. The details of medications are provided in the S5 Table. The total number of other comorbid diseases included in this study were the following: congestive heart failure, dementia, chronic pulmonary diseases, rheumatologic diseases, peptic ulcer diseases, mild, moderate or severe liver diseases, hemiplegia or paraplegia, renal disease, and malignancy. Finally, the proportion of inpatient claims to the total number of outpatient and inpatient claims was calculated to adjust for the severity of diseases.

Data analysis
Descriptive statistics of the participants at the index date were calculated. Kaplan–Meier survival curves were used to compare the overall MACE-free and MALE-free among PAD patients with a different number of metabolic comorbidities. Cox proportional hazards models examined the association between the number of metabolic comorbidities and MACE-free or MALE-free periods. We examined the proportional hazard assumption using plots of the log(-log) survival function. Models were adjusted for the covariates (age, sex, type of insurance, PDC of anti-hypertensive, anti-diabetic, anti-dyslipidemic, and antiplatelet medications), the total number of comorbid diseases, and the proportion of inpatient claims to the total number of claims per patient.

Results
A descriptive analysis of the participants’ characteristics at the index date is shown in Table 1. Approximately 50% of the participants were young-old (65–74 years), and most were men (70%) and insured (89%). PAD patients with hypertension comprised 62% of the sample; 32% were diabetic, and 40% had dyslipidemia. More than half of the population were taking anti-hypertensive medications prescribed as of the index date. Calcium channel blockers (29.50%) were most frequently prescribed, followed by angiotensin II receptor blockers (ARBs) (18.29%), diuretics (18.03%), and alpha or beta-blockers (17.75%). Approximately 17% of the
participants were prescribed anti-diabetic medications. Around 30% of the older patients with PAD were given anti-dyslipidemic medication, with statins as the major prescribed drug (30%). Most patients (80.59%) were prescribed antiplatelet medications and 60% of these participants were given aspirin. The mean number of comorbidities was 0.74 (±0.88) and the mean proportion of inpatient claims to the total number of claims was 0.22 (±0.26).

Less than a quarter of the total participants (24.12%) had no metabolic comorbidities (Table 2). Approximately 30% of the sample had one or two metabolic comorbidities with PAD. Finally, 13% of the participants had all three metabolic comorbidities at the same time.

One-third of the participants (33.73%) experienced MACEs. Approximately 21% had angina pectoris, 10% had an ischemic stroke, and less than 4% had a myocardial infarction during the study period (Table 3). MALE occurred in 17% of the patients, with revascularization (12.01%) as the most frequent procedure. Open surgeries (3.01%), major amputations (1.15%), and minor amputations (2.24%) were rarely performed.
Kaplan-Meier survival curves demonstrated that PAD patients with more metabolic comorbidities had a shorter MACE-free period (Fig 2). The risks of MACE associated with the number of metabolic comorbidities were assessed in 3,122 old PAD patients (Table 4). Adjusted Cox proportional hazards analyses showed additive effects of multiple metabolic comorbidities on MACE. Old PAD patients with metabolic comorbidities had a greater risk of MACE than those without metabolic comorbidity. The adjusted hazard ratio (aHR) of the risk of MACE from having one metabolic comorbidity was 1.69 (95% confidence interval [CI]: 1.38–2.06; p < 0.0001). Having two metabolic comorbidities further increased the risk of MACE (aHR: 

Table 2. Number of participants by the total number of metabolic comorbidities with PAD (n = 3,122).

| Group                          | n (%)     |
|-------------------------------|-----------|
| 1 (No metabolic comorbidity)  | 753 (24.12) |
| 2 (One metabolic comorbidity) | 965 (30.91) |
| 3 (Two metabolic comorbidities) | 985 (31.55) |
| 4 (Three metabolic comorbidities) | 419 (13.42) |

*One metabolic comorbidity means having one metabolic disease among hypertension, diabetes, or dyslipidemia with PAD.

*Two metabolic comorbidities mean having two metabolic diseases among hypertension-diabetes, hypertension-dyslipidemia, or diabetes-dyslipidemia at the same time.

*Three metabolic comorbidities mean having all metabolic diseases including hypertension, diabetes, and dyslipidemia.

Table 3. MACE or MALE occurrence during the study period (n = 3,122).

| MACE                     | n (%)     | MALE                      | n (%)     |
|--------------------------|-----------|---------------------------|-----------|
| Total case               | 1,053 (33.73) | Total case               | 518 (16.59) |
| Myocardial infarction    | 116 (3.72)  | Revascularization         | 375 (12.01) |
| Angina pectoris          | 655 (20.98) | Open surgery              | 94 (3.01)  |
| Ischemic stroke          | 328 (10.51) | Major amputation          | 36 (1.15)  |
|                          |           | Minor amputation          | 70 (2.24)  |

MACE, major adverse cardiovascular events; MALE, major adverse limb events.

Kaplan-Meier survival curves demonstrated that PAD patients with more metabolic comorbidities had a shorter MACE-free period (Fig 2). The risks of MACE associated with the number of metabolic comorbidities were assessed in 3,122 old PAD patients (Table 4). Adjusted Cox proportional hazards analyses showed additive effects of multiple metabolic comorbidities on MACE. Old PAD patients with metabolic comorbidities had a greater risk of MACE than those without metabolic comorbidity. The adjusted hazard ratio (aHR) of the risk of MACE from having one metabolic comorbidity was 1.69 (95% confidence interval [CI]: 1.38–2.06; p < 0.0001). Having two metabolic comorbidities further increased the risk of MACE (aHR:
2.30; 95% CI: 1.90–2.80; p < 0.0001) in older adults with PAD. The presence of all three metabolic comorbidities most significantly increased the risk of MACE (aHR: 3.06; 95% CI: 2.45–3.82; p < 0.0001). Participants under medical aid and veteran insurance were at greater risk of MACE than insured old PAD patients (aHR: 1.24; 95% CI: 1.03–1.49; p = 0.0231). Lastly, the presence of other comorbidities subsequently heightened the risk of MACE to an aHR of 1.12 (95% CI: 1.04–1.20; p = 0.0013).

Kaplan-Meier survival curves showed that PAD patients with more metabolic comorbidities had shorter MALE-free periods (Fig 3). Adjusted Cox proportional hazards analyses showed the additive effects of multiple metabolic comorbidities on MALEs. Old PAD patients with metabolic comorbidities had a greater risk of having MALE than those without metabolic comorbidity (Table 5). Participants with one metabolic comorbidity had an aHR of 1.47 (95% CI: 1.01–1.34; p = 0.0331) for MALE. Having two metabolic comorbidities with PAD also increased the risk of MALE compared to those without metabolic comorbidities (aHR: 1.98; 95% CI: 1.51–2.59; p < 0.0001). When all metabolic comorbidities were present together, there was also a significant increase in the risk of MALE (aHR: 3.22; 95% CI: 2.39–4.35; p < 0.0001). Male PAD patients were at a greater risk of MALE than female PAD patients (aHR: 1.64; 95% CI: 1.32–2.03; p < 0.0001). Young-old PAD patients aged 65–74 years (aHR: 0.79; 95% CI: 0.66–0.96; p = 0.0150) and old-old PAD patients aged 75–84 years (aHR: 0.53; 95% CI: 0.36–0.77; p = 0.0010) had lower risks of MALE than the oldest-old PAD patients aged 85 years and 84 years old.

Table 4. Association of MACE with number of metabolic comorbidity groups (n = 3,122).

| Number of metabolic comorbidities | Hazard ratio | 95% CI  | P* |
|----------------------------------|-------------|--------|----|
| One (vs. none)                   | 1.69        | (1.38, 2.06) | < .0001 |
| Two (vs. none)                   | 2.30        | (1.90, 2.80) | < .0001 |
| Three (vs. none)                 | 3.06        | (2.45, 3.82) | < .0001 |
| Male (vs. Female)                | 1.16        | (1.01, 1.34) | 0.0331 |
| Age                              |             |        |    |
| 75–84 (vs. 65–74)                | 1.01        | (0.89, 1.15) | 0.8840 |
| 85+ (vs. 65–74)                  | 0.79        | (0.62, 1.01) | 0.0567 |
| Anti-hypertensive medication     |             |        |    |
| Diuretic                         | 0.85        | (0.56, 1.30) | 0.4554 |
| ACEI                             | 1.81        | (0.66, 4.99) | 0.2491 |
| ARB                              | 0.73        | (0.46, 1.17) | 0.1928 |
| Alpha & Beta blocker             | 0.63        | (0.38, 1.05) | 0.0738 |
| CCB                              | 0.82        | (0.54, 1.25) | 0.3534 |
| Other                            | 0.74        | (0.47, 1.15) | 0.1818 |
| Anti-diabetic medication         | 1.01        | (0.73, 1.41) | 0.9473 |
| Anti-dyslipidemic medication     | 1.37        | (0.95, 1.97) | 0.0909 |
| Antiplatelet medication          | 0.93        | (0.80, 1.09) | 0.3739 |
| Others* (vs. insured)            | 1.24        | (1.03, 1.49) | 0.0231 |
| Number of comorbidities          | 1.12        | (1.04, 1.20) | 0.0013 |
| %Inpatient setting               | 0.86        | (0.65, 1.12) | 0.2596 |

MACE, major adverse cardiovascular events; CI, confidence interval; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker. Bold indicates significance at p < 0.05.

*Other insurance types included medical aid and veterans.

https://doi.org/10.1371/journal.pone.0268201.t004
above. Lastly, the proportion of inpatient claims to the total number of claims increased the risk of MALE with an aHR of 2.57 (95% CI 1.85–3.58; p < 0.0001).

**Discussion**

Multiple metabolic comorbidities, such as hypertension, diabetes, or dyslipidemia had an additive effect in increasing the risk of MACE and MALE compared to older PAD patients without

Table 5. Association of MALE with number of metabolic comorbidity groups (n = 3,122).

| Number of metabolic comorbidities | Hazard ratio | 95% CI     | P'       |
|----------------------------------|-------------|------------|----------|
| One (vs. none)                   | 1.47        | (0.11, 1.95)| 0.0067   |
| Two (vs. none)                   | 1.98        | (1.51, 2.59)| <.0001   |
| Three (vs. none)                 | 3.22        | (2.39, 4.35)| <.0001   |
| Male (vs. Female)                | 1.64        | (1.32, 2.03)| <.0001   |
| Age                              |             |            |          |
| 75–84 (vs. 65–74)                | 0.79        | (0.66, 0.96)| 0.0150   |
| 85+ (vs. 65–74)                  | 0.53        | (0.36, 0.77)| 0.0010   |
| Anti-hypertensive medication     |             |            |          |
| Diuretic                         | 0.76        | (0.42, 1.38)| 0.3684   |
| ACE                              | 2.98        | (0.41, 21.83)| 0.2816  |
| ARB                              | 1.18        | (0.51, 2.72)| 0.7071   |
| Alpha & beta blocker             | 0.92        | (0.41, 2.06)| 0.8389   |
| CCB                              | 1.10        | (0.53, 2.31)| 0.7982   |
| Other                            | 1.27        | (0.58, 2.75)| 0.5521   |
| Anti-diabetic medication         |             |            |          |
| Anti-dyslipidemic medication     | 1.30        | (0.78, 2.18)| 0.3179   |
| Anti-platelet medication         | 1.45        | (0.81, 2.59)| 0.2169   |
| Others* (vs. insured)            | 0.85        | (0.69, 1.05)| 0.1298   |
| Number of comorbidities          | 0.96        | (0.87, 1.07)| 0.4488   |
| %Inpatient setting               | 2.57        | (1.85, 3.58)| <.0001   |

MALE, major adverse limb events; CI, confidence interval; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker. Bold indicates significance at p < 0.05. Other insurance types included medical aid and veterans.

https://doi.org/10.1371/journal.pone.0268201.t005
metabolic comorbidities. Low socioeconomic status and other comorbidities increased the risk of MACE. Meanwhile, being a male, young-old (65 to 74 years) compared to old-old and oldest-old (75 years and older), and having a higher proportion of inpatient claims out of the total claims increased the risk of MALE.

The risks of MACE or MALE doubled when two metabolic comorbidities were present and tripled when three were present. The additive impacts of metabolic comorbidities on PAD-related adverse outcomes are not supported by prior literature since related studies have not been conducted yet. However, the findings of this study are supported by evidence that hypertension, diabetes, or dyslipidemia aggravates the conditions of older adults with PAD, leading to adverse health outcomes [22, 23]. These results emphasize the need to develop a comprehensive approach for managing underlying metabolic comorbidities in patients suffering from PAD. Our analysis also encourages healthcare providers to implement further interventions for modifiable metabolic risk factors (e.g., high levels of blood pressure, cholesterol, or blood sugar) as preventable measures for adverse MACE and MALE in older PAD patients [24].

The finding that low socioeconomic status was associated with increased risk of MACE in PAD patients was consistent with prior studies. Disadvantaged individuals, such as non-white or low-income patients (e.g., Medicaid recipients) have been reported to experience more metabolic comorbidities that aggravated PAD than the socioeconomically advantaged population [25]. The development of cardiovascular events is also known to be related to some social determinants of health (e.g., income). Low income can be a barrier to accessing healthcare services, leading to chronic metabolic conditions, which are not properly managed [26].

Other diseases coexisting with PAD can also aggravate adverse cardiovascular health problems. The diseases included in the Charlson comorbidity calculation often have chronic characteristics that may interact with existing PAD and are negatively related to the development of major cardiovascular incidents. This finding was supported by a previous study that revealed a significant association between the Charlson comorbidity index score and the readmission of PAD patients [27]. In addition, the individual impact of comorbid diseases (e.g., renal disease) has been studied, and the results suggested that comorbidities play negative roles in the development of MACE in patients [28].

PAD is traditionally known as a male disease. The result that older male adults with PAD had higher risks of MALE than older female adults with PAD was consistent with previous evidence [29]. Women having better amputation-free survival periods than men across all age groups is probably due to socially constructed unhealthy behaviors in males, such as prevalent smoking, which may hasten the progress of PAD [30]. In addition, differences in health-seeking behaviors or healthcare utilization patterns may exist. Older male adults tend not to pursue treatment to manage their conditions, resulting in hospitalizations for revascularization or open surgeries more often than older female adults.

The lower risk of developing MALE in the old-old or oldest-old age groups compared to the young-old age group may reflect the difference in their healthcare utilization patterns. For old-old or oldest-old adults, it could be a reasonable decision to proceed with angiography or procedures considered only when they are experiencing severe symptomatic disabilities [31]. Compared to those age groups, young-old adults with PAD may be more proactive in pursuing revascularization procedures or open surgeries to prolong and improve the quality of life. In a prior study, the risk of mortality and cardiovascular complications was increased among PAD patients aged 80 years and over who underwent lower extremity arterial reconstruction surgery. This may be the case because the risks are higher than the benefits for patients with PAD who are 75 years old and above when they receive medical procedures or surgeries [32]. To adopt an approach that considers patient safety and treatment efficacy, many practitioners may advocate the patients’ stances over aggressive endovascular evaluation. A prior study also
supports this finding on the large reduction in the number of older PAD adults (≥75 years) with diabetes but the main reason for the decline in this age group remains unknown [33, 34].

Lastly, the higher proportion of inpatient claims out of the total claims for PAD showed that amputation, revascularization, and open surgeries were associated with the severity of PAD. Repetitive revascularization was also conducted in older PAD patients. It is possible that some young-old patients cannot manage the symptoms of PAD, and receive repetitive procedures later in life. A previous study also found that the mortality rate was higher for hospitalized PAD patients than for PAD patients having outpatient visits [35]. This reflects the higher risk profiles of PAD patients in inpatient compared to outpatient settings. Thus, the early identification of PAD in outpatient settings will be beneficial in reducing the adverse consequences of repetitive revascularization or open surgeries.

This study is the first attempt to investigate the relationships between multiple metabolic comorbidities that frequently occur with PAD and MACE or MALE. It is also the first to use the national claim data of PAD patients in South Korea. The cohort longitudinal study design allowed for follow-ups from 5 to 8 years for MACE or MALE to explain the influences of multiple metabolic comorbidities. This study also focused on older adults aged 65 and over, who are more vulnerable to diseases like PAD. Lastly, the selection of the study cohort was based on prior studies using administrative data that assured the representativeness of older Korean adults with PAD.

This observational cohort study may be subject to potential confounding factors. We used a Cox proportional hazard model to minimize risks from those confounding factors by adjusting the covariates of demographic factors, medication prescribed, and severity of cases. With these adjustments, this secondary data analysis study inherently cannot account for unmeasured confounding variables, such as smoking behaviors or outcomes of this study. We recognize that these secondary data may not be able to measure patient adherence to medications with 100% certainty for metabolic diseases because this dataset was originally constituted to extract all PAD-diagnosed claims in the national database. This may not reflect the whole case profiles for the metabolic comorbidities. Lastly, administrative claim data could not include PAD patients possibly diagnosed as PAD patients by clinical diagnostic tests, such as the ankle-brachial index (ABI) or self-reporting limb symptoms.

For future studies, a prospective cohort study will be needed to examine the mechanism of multiple metabolic comorbidities over time in PAD-related outcomes of MACE or MALE. Future studies may also investigate the effects of comprehensive interventions for metabolic diseases with PAD to prevent MACE or MALE. With a larger sample size, there may be a need to examine the impact of multiple metabolic comorbidities on specific subgroups of PAD patients and either MACE or MALE to provide evidence for the customized intervention. Lastly, the difference in increased risk for MALE between sexes suggests that future studies may consider a sex-specific approach to examine the effects of multiple metabolic comorbidities on MALE.

Conclusions
Multiple metabolic comorbidities, particularly hypertension, diabetes, and dyslipidemia additively increased the risks of MACE or MALE in older adults. Besides coexisting diseases with PAD, sociodemographic risk factors also increased the risks of adverse outcomes. The findings of this study suggest the need for a comprehensive treatment plan for metabolic comorbidities in older adults with PAD. In addition, healthcare utilization patterns should be considered in designing preventive care programs for older PAD patients with metabolic comorbidities to detect those in their early stages and to provide optimal care for these patients.
Supporting information

S1 Table. International Classification of Disease, 10\textsuperscript{th} revision (ICD-10) codes for metabolic commodities.
(IOCX)

S2 Table. A. Number of participants having hypertension or diabetes. B. Number of participants having hypertension or dyslipidemia. C. Number of participants having diabetes or dyslipidemia.
(IOCX)

S3 Table. International Classification of Disease, 10\textsuperscript{th} revision (ICD-10) codes for MACE.
(IOCX)

S4 Table. Health Insurance Review and Assessment service (HIRA) procedures codes.
(IOCX)

S5 Table. A. Anti-hypertensive medications. B. Anti-diabetic medications. C. Anti-dyslipidemic medications. D. Antiplatelet medications.
(IOCX)

Acknowledgments

All authors thank Dr. Ki Jun Song for his important statistical consulting that guided and improved the methods of this manuscript.

Author Contributions

Conceptualization: Young Shin Park, Mona Choi.

Data curation: Young Shin Park.

Formal analysis: Young Shin Park.

Funding acquisition: Mona Choi.

Methodology: Young Shin Park, Gi Wook Ryu, Mona Choi.

Project administration: Gi Wook Ryu.

Supervision: Mona Choi.

Writing – original draft: Young Shin Park, Gi Wook Ryu.

Writing – review & editing: Young Shin Park, Gi Wook Ryu, Mona Choi.

References

1. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. The Lancet. 2013; 382(9901): 1329–40. https://doi.org/10.1016/S0140-6736(13)61249-0 PMID: 23915883

2. Nehler MR, Duval S, Diao L, Annex BH, Hiatt WR, Rogers K, et al. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. J Vasc Surg. 2014; 60(3): 686–95. https://doi.org/10.1016/j.jvs.2014.03.290 PMID: 24620900

3. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation. 2004; 110 (6): 738–43. https://doi.org/10.1161/01.CIR.0000137913.26087.F0 PMID: 15262830
4. Sampson UK, Fowkes FG, McDermott MM, Criqui MH, Aboyans V, Norman PE, et al. Global and regional burden of death and disability from peripheral artery disease: 21 world regions, 1990 to 2010. Global heart. 2014; 9(1): 145–58. https://doi.org/10.1016/j.ghart.2013.12.008 PMID: 25432124

5. Smolderen KG, Wang K, De Pouvourville G, Brüggenjürgen B, Röther J, Zeymer U, et al. REACH Registry Investigators. Two-year vascular hospitalisation rates and associated costs in patients at risk of atherothrombosis in France and Germany: highest burden for peripheral arterial disease. Eur J Vasc Endovasc Surg. 2012; 43(2): 198–207. https://doi.org/10.1016/j.ejvs.2011.09.016 PMID: 22001145

6. Regensteiner JG, Hiatt WR, Coli JR, Criqui MH, Treat-Jacobson D, McDermott MM, et al. The impact of peripheral arterial disease on health-related quality of life in the Peripheral Artery Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program. Vasc Med. 2008; 13(1): 15–24. https://doi.org/10.1177/1358863X07084911 PMID: 18372434

7. Smolderen KG, Bell A, Lei Y, Cohen EA, Steg PG, Bhatt DL, et al. One-year costs associated with cardiovascular disease in Canada: insights from the REDuction of Atherothrombosis for Continued Health (REACH) registry. Can J Cardiol. 2010; 26(8): e297–305. https://doi.org/10.1016/s0828-282x(10)70437-2 PMID: 20931098

8. Diehm C, Schuster A, Allenberg JR, Darius H, Haberl R, Lange S, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis. 2004; 172(1): 95–105. https://doi.org/10.1016/s0021-9150(03)00204-1 PMID: 14709362

9. Gardner AW, Alauopovic P, Parker DE, Montgomerly PS, Roof A, Casanegra AI. Apolipoprotein profiles in subjects with and without peripheral artery disease. Vasc Med. 2013; 18(3): 129–35. https://doi.org/10.1177/1358863X12470437 PMID: 23720036

10. Meijer WT, Gribbee DE, Hunink MM, Hofman A, Hoes AW. Determinants of peripheral arterial disease in the elderly: the Rotterdam study. Arch Intern Med. 2000; 160(19): 2934–8. https://doi.org/10.1001/archinte.160.19.2934 PMID: 11041900

11. Grenon SM, Vittinghoff E, Owens CD, Conte MS, Whooley M, Cohen BE. Peripheral artery disease and risk of cardiovascular events in patients with coronary artery disease: insights from the Heart and Soul Study. Vasc Med. 2013; 18(4): 176–84. https://doi.org/10.1177/1358863X13493825 PMID: 23835937

12. Kim H, Kim S, Han S, Rane PP, Fox KM, Qian Y, et al. Prevalence and incidence of atherosclerotic cardiovascular disease and its risk factors in Korea: a nationwide population-based study. BMC Public Health. 2019; 19(1): 1.

13. Mahoney EM, Wang K, Keo HH, Duval S, Smolderen KG, Cohen DJ, et al. Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States. Cir Cardiovasc Qual Outcomes. 2010; 3(6): 642–51. https://doi.org/10.1161/CIRCOUTCOMES.109.930735 PMID: 20940249

14. Saely CH, Schindewolf M, Zanolin D, Heinzelz CF, Vonbank A, Silbernagel G, et al. Single and combined effects of peripheral artery disease and of type 2 diabetes mellitus on the risk of cardiovascular events: A prospective cohort study. Atherosclerosis. 2018; 279: 32–7. https://doi.org/10.1016/j.atherosclerosis.2018.09.031 PMID: 30399464

15. Koo BK, Lee CH, Yang BR, Hwang SS, Choi NK. The incidence and prevalence of diabetes mellitus and related atherosclerotic complications in Korea: a National Health Insurance Database Study. PloS One. 2014; 9(10): e110650. https://doi.org/10.1371/journal.pone.0110650 PMID: 25297114

16. Choi SY, Yang BR, Kang HJ, Park KS, Kim HS. Contemporary use of lipid-lowering therapy for secondary prevention in Korean patients with atherosclerotic cardiovascular diseases. Korean J Intern Med. 2020; 35(3): 593. https://doi.org/10.3904/kjim.2018.312 PMID: 31752475

17. Kim J, Chun DJ, Kim S, Yang HJ, Kim JH, Cho JH, et al. Trends in lower limb amputation in patients with diabetic foot based on vascular intervention of peripheral arterial disease in Korea: a population-based nationwide study. J Korean Med Sci. 2019; 34(26): e178. https://doi.org/10.3346/jkms.2019.34.e178 PMID: 31269542

18. Park YY, Joh JH, Han SA, Kim SH, Cho S, Park HC, et al. National trends for the treatment of peripheral arterial disease in Korea between 2004 and 2013. Ann Surg Treat Res. 2015; 89(6): 319–24. https://doi.org/10.1474/astr.2015.89.6.319 PMID: 26665127

19. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. The Lancet. 2004; 363(9426): 2022–31. https://doi.org/10.1016/S0140-6736(04)16451-9 PMID: 15207952

20. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007; 297(2): 177–86. https://doi.org/10.1001/jama.297.2.177 PMID: 17213401

21. Willey J, Mentias A, Vaughn-Sarrazin M, McCoy K, Rosenthal G, Girotra S. Epidemiology of lower extremity peripheral artery disease in veterans. J Vasc Surg. 2018; 68(2): 527–35. https://doi.org/10.1016/j.jvs.2017.11.083 PMID: 29588132
22. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015; 116(9):1509–26. https://doi.org/10.1161/CIRCRESAHA.116.303849 PMID: 25908725

23. Fowkes FG, Aboyans V, Fowkes FJ, McDermott MM, Sampson UK, Criqui MH. Peripheral artery disease: epidemiology and global perspectives. Nat Rev Cardiol. 2017; 14(3):156–70. https://doi.org/10.1038/nrcardio.2016.179 PMID: 27853158

24. Vanassche T, Verhamme P, Anand SS, Shestakovska O, Fox KA, Bhatt DL, et al. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: an analysis of the randomized, double-blind COMPASS trial. Eur J Prev Cardiol. 2020; 27(3): 296–307. https://doi.org/10.1002/eurj.201900821 PMID: 31615291

25. Kalbaugh CA, Loehr L, Wruck L, Lund JL, Matsushita K, Bengtson LG, et al. Frequency of care and mortality following an incident diagnosis of peripheral artery disease in the inpatient or outpatient setting: the ARIC (atherosclerosis risk in communities) study. J Am Heart Assoc. 2018; 7(8): e007332. https://doi.org/10.1161/JAHA.117.007332 PMID: 29654201

26. Nguyen LL, Henry AJ. Disparities in vascular surgery: is it biology or environment?. J Vasc Surg. 2010; 51(4): S36–41. https://doi.org/10.1016/j.jvs.2010.02.003 PMID: 20346336

27. Vogel TR, Kruse RL. Risk factors for readmission after lower extremity procedures for peripheral artery disease. J Vasc Surg. 2013; 58(1): 90–7. https://doi.org/10.1016/j.jvs.2012.12.031 PMID: 23541547

28. Bourrier M, Ferguson TW, Embil JM, Rigatto C, Komenda P, Tangri N. Peripheral artery disease: its adverse consequences with and without CKD. Am J Kidney Dis. 2020; 75(5): 705–12. https://doi.org/10.1053/j.ajkd.2019.08.028 PMID: 31879218

29. Humphries MD, Brunson A, Li CS, Melnikow J, Romano PS. Amputation trends for patients with lower extremity ulcers due to diabetes and peripheral artery disease using statewide data. J Vasc Surg. 2016; 64(6): 1747–55. https://doi.org/10.1016/j.jvs.2016.06.096 PMID: 27670653

30. Heidari S, Babor TF, De Castro P, Tort S, Curno M. Sex and gender equity in research: rationale for the SAGER guidelines and recommended use. Res Integr Peer Rev. 2016; 1(1): 1–9. https://doi.org/10.1186/s41073-016-0007-6 PMID: 29451543

31. Isner JM, Rosenfield K. Redefining the treatment of peripheral artery disease. Role of percutaneous revascularization. Circulation. 1993; 88(4): 1534–57. https://doi.org/10.1161/01.cir.88.4.1534 PMID: 8403302

32. Shiraki T, Iida O, Takahara M, Okamoto S, Kitano I, Tsuji Y, et al. Predictive scoring model of mortality after surgical or endovascular revascularization in patients with critical limb ischemia. J Vasc Surg. 2014; 60(2): 383–9. https://doi.org/10.1016/j.jvs.2014.02.059 PMID: 24726827

33. Gatti C, Cecchini S, Fabbiotti P, Romagnoli F, Ricci S. Endovascular treatment of diabetic peripheral arterial disease in older and oldest old patients: a retrospective study. Aging Clin Exp Res. 2018; 30(2): 205–7. https://doi.org/10.1007/s40520-017-0760-5 PMID: 28584901

34. Li Y, Burrows NR, Gregg EW, Albright A, Geiss LS. Declining rates of hospitalization for nontraumatic lower-extremity amputation in the diabetic population aged 40 years or older: US, 1988–2008. Diabetes Care. 2012; 35(2): 273–7. https://doi.org/10.2337/dc11-1360 PMID: 22275440

35. Ezekowitz JA, Kaul P, Bakal JA, Quan H, McAlister FA. Trends in heart failure care: has the incident diagnosis of heart failure shifted from the hospital to the emergency department and outpatient clinics?. Eur J Heart Fail. 2011; 13(2): 142–7. https://doi.org/10.1093/eurjhf/hfq185 PMID: 20959343